5 Key Takeaways

• 1

  Harrow acquired the US commercial rights to Triesence in January 2023, reviving the product after a two-year absence from the market.

• 2

  The relaunch involved meeting updated FDA standards for manufacturing and testing, requiring significant adjustments to the production process.

• 3

  Harrow established a 5-year strategic supply agreement with its primary manufacturer to ensure a reliable long-term supply of Triesence.

• 4

  The company implemented a comprehensive testing protocol for Triesence, including particle size analysis and supply chain integrity evaluations.

• 5

  Harrow's medical affairs team engages with physicians to educate them on Triesence, facilitating its appropriate use in clinical practice.